Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction.

Area of Science:

• Cardiology
• Immunology
• Clinical Risk Stratification

Background:

• Myocardial infarction (MI) risk stratification is crucial for patient outcomes.
• Platelet Fc gamma RIIa (pFCG) expression is a potential biomarker for adverse events post-MI.
• Existing clinical risk factors alone may not fully capture individual patient risk.

Purpose of the Study:

• To evaluate the prognostic value of clinical risk factors in MI patients.
• To assess the added prognostic value of the pFCG test in combination with clinical risk.
• To determine if pFCG testing can refine risk stratification and guide treatment strategies.

Main Methods:

• A prospective, non-interventional trial enrolled 749 patients hospitalized with type 1 MI.
• Inclusion criteria required at least two clinical risk factors (e.g., age ≥65, multi-vessel CAD, prior MI, CKD, diabetes).
• Platelet Fc gamma RIIa (pFCG) expression was quantified by flow cytometry; high and low expression were defined by a threshold. The primary endpoint was a composite of MI, stroke, and death.

Main Results:

• Patients with more clinical risk factors exhibited a higher risk of subsequent MI, stroke, or death within one year.
• The event rates were 10.2% (2 factors), 14.4% (3 factors), and 35.6% (4-5 factors).
• The pFCG test identified distinct higher-risk and lower-risk cohorts across all levels of clinical risk.

Conclusions:

• Both clinical risk assessment and the pFCG test are prognostic indicators in MI patients.
• The pFCG test provides incremental prognostic information, refining risk stratification beyond clinical factors alone.
• The pFCG test may serve as a valuable tool for balancing ischemic and bleeding risks to optimize treatment strategies.